Houston firm wins $10.8M CPRIT grant to advance brain tumor drug

02/25/2014 | Genetic Engineering & Biotechnology News

The Cancer Prevention and Research Institute of Texas awarded Houston-based drugmaker DNAtrix a $10.8 million grant to advance its experimental drug DNX-2401, an oncolytic virus, for treatment of malignant glioma. DNX-2401 selectively attacks tumor cells using a genetically modified adenovirus. The drug, in combination with temozolomide, is being tested against recurrent glioblastoma in a Phase Ib study.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director Medical Affairs
Edwards Lifesciences
Irvine, CA
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA
Medical Director - Physician
Willamette Valley Community Health
Salem, OR
Area Reimbursement Manager (CT, MA, MD, ME, NH, NJ, NY, PA, VT)
SI-BONE, INC
Multiple Locations, SL_Multiple Locations
Medical Director - Physician
Willamette Valley Community Health
Salem, OR